Atlanta Consulting Group Advisors LLC Buys Shares of 24,054 Kenvue Inc. (NYSE:KVUE)

Atlanta Consulting Group Advisors LLC bought a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,054 shares of the company's stock, valued at approximately $556,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its holdings in shares of Kenvue by 23.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company's stock worth $2,887,773,000 after purchasing an additional 25,238,112 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Kenvue by 9.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 79,863,967 shares of the company's stock worth $1,451,927,000 after buying an additional 7,023,047 shares during the last quarter. Bank of New York Mellon Corp raised its position in Kenvue by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company's stock worth $789,813,000 after buying an additional 7,546,362 shares during the last quarter. American Century Companies Inc. raised its position in Kenvue by 20.7% during the 2nd quarter. American Century Companies Inc. now owns 27,382,644 shares of the company's stock worth $497,816,000 after buying an additional 4,700,697 shares during the last quarter. Finally, Van ECK Associates Corp raised its position in Kenvue by 110.9% during the 2nd quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company's stock worth $372,880,000 after buying an additional 10,783,258 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of analyst reports. JPMorgan Chase & Co. raised their price objective on shares of Kenvue from $24.00 to $25.00 and gave the stock an "overweight" rating in a research note on Friday, October 11th. Bank of America lifted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, October 22nd. Piper Sandler lifted their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research note on Monday, September 23rd. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. Finally, Jefferies Financial Group initiated coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $22.64.

Kenvue Price Performance

KVUE traded down $0.09 on Monday, hitting $23.73. 14,591,632 shares of the company's stock were exchanged, compared to its average volume of 18,038,559. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.13. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $22.77 and a 200-day moving average price of $20.71. The stock has a market cap of $45.50 billion, a price-to-earnings ratio of 43.24, a P/E/G ratio of 2.16 and a beta of 1.36.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion for the quarter, compared to analysts' expectations of $3.92 billion. During the same quarter in the previous year, the company posted $0.31 EPS. The firm's quarterly revenue was down .4% on a year-over-year basis. As a group, equities analysts anticipate that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.46%. Kenvue's dividend payout ratio is presently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.